Testosterone and androstenedione are metabolized by 5a-and 5-reductases to androsterone (A) and etiocholanolone (E), respectively. These are excreted in the urine as conjugates, and the A/E ratio in normal men is usually 1 .5 (as opposed to 1 in women) because of the high 5a-reductase activity in the prostate. The NE ratio can be determined simply by gas chromatography after acid hydrolysis of a urine sample, extraction of steroids, and formation of tnmethylsilylderivatives. A timed collectionof urine is unnecessary because the ratio of A/E is used rather than absolute values. In men sufferingfrom benign prostate hypertrophy who are treated with Finasteride (a 5a-reductase Inhibitor), the NE ratio decreases to <0.5. The NE ratio decrease can be detected long before there is clinical improvement. 5-reduction, the 5a-reductase inhibitor ought to considerably lower the A/E ratio.
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Materials and Methods

Finasteride
(MK-906), the drug used in this study, is
This compound (Proscar,5 Merck, Sharp & Dohme) is a 4-aza steroid competitive inhibitor of human 5a-reductase.
Inhibition of 5a-reductase results in a decrease in target organ concentrations of dihydrotestosterone (DHT). Three conditions are the principal potential indications for using this drug BPH, carcinoma of the prostate, and female hirsutism.
In all three conditions, the androgen-responsive target organ is primarily stimulated by DHT. BPH is presently under investigation with this drug.
Patients
As part of an international multicenter study group, we treated 23 elderly BPH patients with Finasteride for a period of up to one year. The study was double-blind, and patients received placebo or 1 or 5 mg of the drug.
All patients were ernmined clinically twice before treatment began and every month thereafter. Various urological as well as blood indexes were monitored. For this report, patients had to have been in the study for at least one month, and most had been in the study for more than three months. Fresh urine specimens were collected from each patient in the morning (between 0830 and 0930).
At the end of one year, we uncoded the list of patients and divided the results into three groups: group A, patients taking a placebo (age-matched control subjects; 11 men); group B, patients taking 1 mg of drug (6 men); and group C, patients taking 5 mg of drug (11 men). Because the trial was extended on an open basis, five patients who had been originally on placebo were treated with 5 mg of drug (group D), and three patients previously treated for one year with 1 mg of drug were transferred to 5 mg of drug (group E). The AlE ratio was measured after one month of treatment with 5 mg of drug in groups D and E.
Determinationof the A/E Ratio
Androsterone and etiocholanolone were measured in fresh urine samples by our previously published method (6) involving gas chromatography of trimethylsilyl derivatives of the steroids after acid hydrolysis of the The mean values of the A/B ratio groups A, B, and C, respectively, were 1.25 (SD 0.59), 0.33 (SD 0.08), and 0.29 (SD 0.08). There was a significant difference between control subjects and members of groups B and C (P <0.001 with the unpaired Student's t-test). There was no significant difference between groups B and C. and patients switched from 1 to 5 mg of drug (E) Figure 2 depicts the five men who were switched from placebo to 5 mg of drug (group D). As can be seen, a sharp decline was noted in the A/E ratio after one month of treatment. There was a minimal further decrease in AlE ratios in those in group E.
From the approximately equal mean values of the AlE ratio in groups B and C and from the changes shown in Figure 2 , it can be seen that 1 mg of Finasteride per day decreases A/E similarly to the 5-mg/day dosage.
The A/E ratio is a good measure of 5a-reductase activity relative to the activity of 513-reductase. The most striking results are those in group D, where patients whose ratio had been determined previously were checked again after taking the drug. These patients were exnmined on their first visit to the clinic after the transfer from placebo to drug. The time interval was approximately one month, and it is possible that a decreased A/E ratio could be discerned after less time. However, a check on the efficacy of the drug regarding changes in A/E ratio after only one month is much more striking than the urologic examination, which requires several months for significant clinical changes to appear. Therefore, this test may have several clinical applications, including ensuring patient compliance. The drug will have to be taken for prolonged periods of time, if not indefinitely, to prevent the prostate from growing, and such a simple, noninvasive test to assess compliance will be useful.
The In conclusion, measuring the A/E ratio in urine is a simple and efficient way of monitoring 5a-reductase activity. This method might be useful for selecting patients for 5a-reductase inhibitor treatment, to optimize results as well as to monitor patient compliance.
